Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Vox Sanguinis|April 26, 2007
Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years' experienceC Politis, L Kavallierou, S Hantziara, et al.Leukemia|September 5, 2008
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesisE Terpos, E Kastritis, M Roussou, et al.European Journal of Haematology|February 13, 2001
Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study GroupK Zervas, A Pouli, B Gregoraki, et al.Journal of Endocrinological Investigation|December 14, 1999
Structure-function correlations of growth hormone or/and prolactin-producing pituitary adenomas: an in vitro study with the reverse hemolytic plaque assayE Thodou, G Kontogeorgos, E Kyrodimou, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001
Thalidomide and dexamethasone combination for refractory multiple myelomaM A Dimopoulos, K Zervas, G Kouvatseas, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2007
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study GroupK Zervas, D Mihou, E Katodritou, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemiaM A Dimopoulos, G Hamilos, K Zervas, et al.Leukemia|February 20, 2009
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)E Kastritis, K Zervas, A Symeonidis, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 25, 2004
Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre studyH Giamarellou, E J Giamarellos-Bourboulis, P Repoussis, et al.British Journal of Haematology|November 13, 2001
Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuriaD J Araten, D Swirsky, A Karadimitris, et al.Pageof 3